Loading...
Loading...
Browse all stories on DeepNewz
VisitMedicare to Cover Eli Lilly's Zepbound for Sleep Apnea Following FDA Approval
Jan 8, 2025, 08:34 PM
The Centers for Medicare & Medicaid Services (CMS) has announced that Medicare will cover Eli Lilly's Zepbound for the treatment of obstructive sleep apnea (OSA). This decision follows the drug's recent FDA approval, making Zepbound the first medication specifically approved for moderate-to-severe OSA. The coverage under Medicare Part D is expected to enhance the drug's market potential, as it is already recognized as a significant treatment option for obesity-related conditions.
View original story
$500 million to $1 billion • 25%
More than $2 billion • 25%
$1 billion to $2 billion • 25%
Less than $500 million • 25%
Yes • 50%
No • 50%
More than $300 million • 25%
$201 million to $300 million • 25%
$100 million to $200 million • 25%
Less than $100 million • 25%
Yes • 50%
No • 50%
1 million to 2 million • 25%
More than 2 million • 25%
Less than 500,000 • 25%
500,000 to 1 million • 25%
200,000 to 300,000 • 25%
More than 300,000 • 25%
Less than 100,000 • 25%
100,000 to 200,000 • 25%
Stock price increases by 10% to 15% • 25%
Stock price increases by less than 5% • 25%
Stock price increases by more than 15% • 25%
Stock price increases by 5% to 10% • 25%